Clearmind Medicine簽署開發協議，推進其專有無致幻神經塑性藥物Meai的鼻內製劑研發

美股速遞

02/06

Clearmind Medicine Inc. 近日與Polyrizon Ltd. 達成一項開發合作協議，旨在加速其專有無致幻神經塑性化合物Meai的鼻內製劑研發進程。該合作將結合Clearmind在神經科學領域的專長與Polyrizon在藥物遞送技術方面的優勢，共同推進新型治療方案的開發。此次合作標誌着公司在非致幻性神經可塑性藥物研發領域邁出重要一步。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1173106061"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173106061\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173106061?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-02-06 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173106061","market":"us","top_or_hot":-1,"title":"Clearmind Medicine簽署開發協議，推進其專有無致幻神經塑性藥物Meai的鼻內製劑研發","media":"美股速遞","content":"<p>Clearmind Medicine Inc. 近日與Polyrizon Ltd. 達成一項開發合作協議，旨在加速其專有無致幻神經塑性化合物Meai的鼻內製劑研發進程。該合作將結合Clearmind在神經科學領域的專長與Polyrizon在藥物遞送技術方面的優勢，共同推進新型治療方案的開發。此次合作標誌着公司在非致幻性神經可塑性藥物研發領域邁出重要一步。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearmind Medicine簽署開發協議，推進其專有無致幻神經塑性藥物Meai的鼻內製劑研發</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearmind Medicine簽署開發協議，推進其專有無致幻神經塑性藥物Meai的鼻內製劑研發\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速遞 </p>\n<p class=\"h-time smaller\">2026-02-06 20:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Clearmind Medicine Inc. 近日與Polyrizon Ltd. 達成一項開發合作協議，旨在加速其專有無致幻神經塑性化合物Meai的鼻內製劑研發進程。該合作將結合Clearmind在神經科學領域的專長與Polyrizon在藥物遞送技術方面的優勢，共同推進新型治療方案的開發。此次合作標誌着公司在非致幻性神經可塑性藥物研發領域邁出重要一步。</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMND","symbol_name":"Clearmind Medicine, Inc.","start_time":0,"source_url":"","article_id":"1173106061","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173106061","pubTimestamp":1770382573,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速遞","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Clearmind Medicine Inc. 近日與Polyrizon Ltd. 達成一項開發合作協議，旨在加速其專有無致幻神經塑性化合物Meai的鼻內製劑研發進程。該合作將結合Clearmind在神經科學領域的專長與Polyrizon在藥物遞送技術方面的優勢，共同推進新型治療方案的開發。此次合作標誌着公司在非致幻性神經可塑性藥物研發領域邁出重要一步。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CMND":"Clearmind Medicine, Inc.","PLRZ":"Polyrizon Ltd.","BK4007":"制药"},"translate_title":"Clearmind Medicine signs development agreement to advance intranasal formulation of its proprietary non-hallucinogenic neuroplastic drug Meai","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMND":1,"PLRZ":1},"content_text":"Clearmind Medicine Inc. 近日與Polyrizon Ltd. 達成一項開發合作協議，旨在加速其專有無致幻神經塑性化合物Meai的鼻內製劑研發進程。該合作將結合Clearmind在神經科學領域的專長與Polyrizon在藥物遞送技術方面的優勢，共同推進新型治療方案的開發。此次合作標誌着公司在非致幻性神經可塑性藥物研發領域邁出重要一步。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}